Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi Sells 3,195 Shares of Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,195 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $85,018.95. Following the transaction, the chief financial officer now directly owns 148,509 shares of the company’s stock, valued at $3,951,824.49. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, October 15th, Balaji Gandhi sold 864 shares of Phreesia stock. The shares were sold at an average price of $21.03, for a total transaction of $18,169.92.

Phreesia Stock Performance

NYSE:PHR opened at $28.42 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of -19.33 and a beta of 0.94. The firm’s fifty day moving average price is $22.50 and its 200 day moving average price is $22.53. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $29.16.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.58) earnings per share. On average, sell-side analysts expect that Phreesia, Inc. will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Versor Investments LP acquired a new stake in Phreesia in the third quarter valued at $694,000. Zacks Investment Management purchased a new position in shares of Phreesia in the 3rd quarter valued at about $631,000. Sei Investments Co. increased its holdings in shares of Phreesia by 135.3% in the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after purchasing an additional 95,058 shares in the last quarter. State Street Corp lifted its stake in shares of Phreesia by 7.1% in the third quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after purchasing an additional 88,517 shares during the period. Finally, Barclays PLC boosted its holdings in Phreesia by 83.6% during the third quarter. Barclays PLC now owns 94,929 shares of the company’s stock worth $2,163,000 after buying an additional 43,225 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Tuesday, December 10th. Robert W. Baird dropped their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. KeyCorp boosted their target price on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday. JMP Securities reiterated a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a research note on Tuesday, December 10th. Finally, Truist Financial boosted their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Eleven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $30.64.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.